EIM Via the Myolex MScan As an ALS Biomarker
(ElectricALS Trial)
Trial Summary
What is the purpose of this trial?
Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objective, require minimal training, be easily standardized, cost-efficient, and have the potential to be applied effectively at home. There has been a push to identify accurate, objective biomarkers of ALS progression. In this study, the investigators propose to use Electrical impedance myography (EIM) to evaluate the progression of the disease. Work has shown that the EIM 50 kilohertz (kHz) phase value from one or more muscles, followed sequentially, can serve as an effective overall biomarker for assessing the rate of ALS progression for a single person.
Research Team
Masumeh Hatami, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Seward Rutkove, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Eligibility Criteria
Inclusion Criteria
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
United States Department of Defense
Collaborator